Login to Your Account



Financings Roundup

Esperion Prices Upsized $70M IPO for Statin Alternative Work

By Jennifer Boggs
Managing Editor

Thursday, June 27, 2013

Following in the footsteps of upsized initial public offerings (IPOs) from PTC Therapeutics Inc. and Bluebird Bio, Plymouth, Mich.-based Esperion Therapeutics Inc. priced an IPO to raise $70 million – $80.5 million if underwriters exercise overallotments in full – to support midstage testing of its lead compound, ETC-1002, as an alternative to statin therapy in lowering LDL-cholesterol (LDL-C).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription